News and Announcements
Analytica Granted Patent Protection in Japan for PeriCoach®
- Published February 22, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Analytica (ASX:ALT) has been granted patent protection in Japan for the PeriCoach®System’s unique technology. The company’s leading product is an e-health treatment system for women who suffer Stress Urinary Incontinence. PeriCoach has created a device, web portal and smartphone app. This device evaluates the activity in the pelvic floor muscles. The information is then transmitted to a smartphone app and can loaded to PeriCloud where physicians can monitor patient progress via this portal.
KEY TAKEAWAYS:
- Patents on the PeriCoach force sensors have now issued in China and Japan.
- Patents pending in US, India, Brazil, Australia, and Europe.
- Japan has enormous market potential for a global licensee with an estimated 15.8 million women aged 15-85+ currently suffering the effects of Urinary Incontinence.
Analytica has kept PeriCoach as their top priority to ensure that this becomes a global product. With increased awareness of urinary incontinence, and a growing demand towards conservative treatment solutions.
Analytica CEO Geoff Daly said – “Patent protection is a long process, often many taking years before patents are issued. We are diligently working behind the scenes to ensure that we get the full benefit from the hard work and innovations of my product development team. Intellectual property rights are always critical in licencing negotiations as it affords the licencing partner freedom to operate in the world’s most commercially attractive markets.”
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
